Cargando…
Molecular Profiling Defines Distinct Prognostic Subgroups in Childhood AML: A Report From the French ELAM02 Study Group
Despite major treatment improvements over the past decades, pediatric acute myeloid leukemia (AML) is still a life-threatening malignancy with relapse rates up to 30% and survival rates below 75%. A better description of the pattern of molecular aberrations in childhood AML is needed to refine progn...
Autores principales: | Marceau-Renaut, Alice, Duployez, Nicolas, Ducourneau, Benoît, Labopin, Myriam, Petit, Arnaud, Rousseau, Alexandra, Geffroy, Sandrine, Bucci, Maxime, Cuccuini, Wendy, Fenneteau, Odile, Ruminy, Philippe, Nelken, Brigitte, Ducassou, Stéphane, Gandemer, Virginie, Leblanc, Thierry, Michel, Gérard, Bertrand, Yves, Baruchel, André, Leverger, Guy, Preudhomme, Claude, Lapillonne, Hélène |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745946/ https://www.ncbi.nlm.nih.gov/pubmed/31723759 http://dx.doi.org/10.1097/HS9.0000000000000031 |
Ejemplares similares
-
Maintenance Therapy With Interleukin-2 for Childhood AML: Results of ELAM02 Phase III Randomized Trial
por: Petit, Arnaud, et al.
Publicado: (2018) -
Is Acute Myeloblastic Leukemia in Children Under 2 Years of Age a Specific Entity? A Report from the FRENCH ELAM02 Study Group
por: Blais, S., et al.
Publicado: (2019) -
Germline pathogenic variants in transcription factors predisposing to pediatric acute myeloid leukemia: results from the French ELAM02 trial
por: Fenwarth, Laurène, et al.
Publicado: (2020) -
Prognostic impact of RUNX1 mutations and deletions in pediatric acute myeloid leukemia: results from the French ELAM02 study group
por: Lew-Derivry, Lucille, et al.
Publicado: (2023) -
Leukemia Cutis in Childhood Acute Myeloid Leukemia: Epidemiological, Clinical, Biological, and Prognostic Characteristics of Patients Included in the ELAM02 Study
por: Gouache, Elodie, et al.
Publicado: (2018)